Book a Meeting

Science Advances

Antibody-dependent cytotoxicity (ADCC) is a key mechanism by which the immune system responds to pathogens and cancer cells. Recent advancements in understanding and harnessing ADCC have led to several noteworthy scientific advances:

Engineering Monoclonal Antibodies (mAbs): Scientists have made significant progress in engineering monoclonal antibodies to enhance their ADCC activity. This includes modifying the Fc region of antibodies to optimize binding to Fcγ receptors on immune cells like natural killer (NK) cells, which are key effectors of ADCC.

Fig.1 Structure of mAb and mechanism of action in different reactions. (van der Horst, 2020)Fig.1 Structure of mAb and mechanism of action in different reactions.1

Overall, these scientific advances have significantly advanced our understanding of ADCC and its role in immune surveillance and therapy. Continued research in this field holds promise for the development of more effective immunotherapies for cancer, infectious diseases, and other conditions. Here, Creative Biolabs provides the latest research information to share the scientific results of ADCC with you!

Human Anti-M2 Ab1-10 Monoclonal Antibody (mAb) & ADCC

Here, we will mainly introduce you to a study which showed the effect of AB1-10 mAb-mediated NK cells on M2-expressing cells in ADCC.

Predict the ADCC Extent: CD2posCD16Apos NK Phenotype

Here, we will mainly introduce you to a study on the extent to which ADCC is predicted by the D2posCD16Apos NK phenotype.

Antibody-cell Conjugation: Enhance Targeted Cancer Immunotherapy

Here, we will mainly introduce you to a study: nanobodies or antibodies promote the contact between immune effector cells and target cancer cells through site-selective tyrosine reaction, enhancing the killing effect of cancer cells.

ADCC Combination Therapy

Here, we will mainly introduce you to a study on the effect of enhancing ADCC through combination therapy. Among them, we briefly list the experimental data related to ADCC.


  1. van der Horst.; et al. "Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies." Cancers. (2020) 12,10 3041.


Creative Biolabs provides luciferase-based ADCC assay. This Jurkat cell based assay is pioneered by Creative Biolabs, and the methodology is very well accepted by the field. See attached ADCC Reporter Assay Protocol for further details. 

All products and services are for Research Use Only. Do Not use in humans.


ADCC Assay WT vs AfucoTM Mabs  Visit


Antibody Fc Engineering: Towards Better Therapeutics  Visit


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *